+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dengue Testing Market - Global Forecast to 2030- Product Image
Dengue Testing Market - Global Forecast to 2030- Product Image
New

Dengue Testing Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 191 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6083753
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Dengue Testing Market grew from USD 527.02 million in 2024 to USD 558.61 million in 2025. It is expected to continue growing at a CAGR of 5.77%, reaching USD 738.13 million by 2030.

Dengue fever remains a pressing global health challenge, with outbreaks spanning tropical and subtropical regions and imposing significant clinical and economic burdens. Accurate and timely detection is critical for effective patient management, outbreak containment, and public health decision-making. Over the past decade, advances in molecular biology, immunoassay design, and point-of-care technologies have reshaped the diagnostic landscape, enabling earlier detection and more precise differentiation of dengue infection stages. These innovations, coupled with evolving regulatory frameworks and changing payer dynamics, have created both opportunities and complexities for manufacturers, laboratories, and health systems. This executive summary introduces the current state of dengue testing, highlights the transformative factors influencing the market, and outlines actionable insights to guide investment, strategic planning, and collaborative initiatives. By synthesizing recent regulatory shifts, tariff implications, segmentation analysis, regional variations, and competitive positioning, this report equips stakeholders with the clarity required to navigate the rapidly evolving diagnostic ecosystem.

Transformative Shifts Reshaping Dengue Testing

The dengue testing market is undergoing transformative shifts driven by technological breakthroughs, integration of digital health tools, and heightened focus on outbreak preparedness. First, the emergence of high-sensitivity nucleic acid amplification methods, including optimized RT-PCR protocols, is enabling detection of low viral loads within the first days post-exposure, thereby improving early clinical intervention. Second, the proliferation of compact lateral flow assays and immunochromatographic card tests that deliver results in under 30 minutes is empowering decentralized testing in resource-limited settings. Third, incorporation of biosensor platforms and wearable devices is fostering continuous monitoring possibilities, transforming patient management paradigms beyond episodic testing. Concurrently, software advancements in data management systems and diagnostic software services are streamlining result interpretation, quality control, and epidemiological surveillance. Finally, public-private partnerships and novel funding mechanisms are catalyzing R&D efforts, accelerating regulatory approvals, and promoting access in endemic regions. These combined forces are redefining market dynamics by prioritizing rapid, accurate, and scalable solutions, compelling stakeholders to adapt strategy, invest in complementary capabilities, and foster cross-sector collaborations.

Cumulative Impacts of U.S. Tariffs Implemented in 2025

Beginning in early 2025, the imposition of additional tariffs on imported diagnostic reagents, instruments, and consumables by the United States has exerted measurable pressure on supply chains and product pricing. Manufacturers reliant on offshore production of antibodies, antigens, and nucleic acid reagents have experienced cost increases that, when passed downstream, have impacted clinical lab budgets and reimbursement negotiations. Instrument providers face elevated import duties on analyzers and detection systems, prompting several to reevaluate manufacturing footprints and consider near-shoring strategies. In response, contract development organizations are diversifying supplier networks and accelerating adoption of alternative reagents that remain tariff-exempt. Diagnostic software providers, whose offerings combine digital platforms with connected hardware, have also recalibrated licensing and service models to maintain competitive total cost of ownership. Collectively, these tariff-driven adjustments have underscored the importance of supply chain resilience and cost-mitigation planning, compelling industry participants to adopt lean inventory practices, invest in domestic manufacturing partnerships, and explore collaborative procurement consortia.

Multi-Dimensional Segmentation Yields Strategic Insights

Insight into customer preferences and technology adoption emerges when the market is dissected across multiple dimensions. When segmented by test type, analyses cover molecular tests, subdividing into nucleic acid amplification tests and reverse transcription polymerase chain reaction, rapid diagnostic tests further broken down into immunochromatographic card tests and lateral flow assays, and serological tests encompassing enzyme-linked immunosorbent assay and Mac-ELISA. Segmenting by product type reveals demand spreads among instruments-spanning analyzers and detection systems-reagents and kits, which include antibodies and antigens, and software and services, covering data management systems and diagnostic software services. Examining end users highlights activity in academic research institutes, blood banks, diagnostic centers differentiated into clinician-operated labs and independent diagnostic labs, as well as hospitals and clinics, which encompass private clinics and public hospitals. Detection time analysis distinguishes early detection within one to three days post-exposure and four to six days post-exposure from late detection at seven days and beyond. Technology segmentation differentiates immunochemistry platforms, including fluorescent immunoassay and radioimmunoassay, molecular diagnostics such as genomic sequencing and microarray technologies, and point-of-care technology integrating biosensors and wearable devices. The market’s test nature divides into qualitative and quantitative tests, while patient group analysis segments adult, elderly, and pediatric patients, further distinguishing adolescents and neonates. This multifaceted segmentation underscores evolving end-user needs, guiding tailored product development and market entry strategies.

Regional Variations and Market Drivers

Regional analysis reveals pronounced differences in testing infrastructure, regulatory pathways, and demand drivers. In the Americas, strong laboratory networks and robust reimbursement frameworks support widespread adoption of high-throughput RT-PCR and automated ELISA platforms, while point-of-care testing gains traction in rural and underserved communities. Europe, Middle East & Africa exhibit a blend of advanced molecular diagnostics in Western Europe, streamlined approvals fostering rapid hepatitis and dengue co-screening, and growing reliance on lateral flow tests across Middle Eastern and African markets due to lower capital requirements. In Asia-Pacific, high population density and periodic outbreaks drive sustained investment in rapid diagnostic tests and mobile testing units, with several governments subsidizing biosensor and wearable device pilots. Such regional nuances inform strategic allocation of R&D budgets, localization of manufacturing, and partner selection to maximize market penetration and align with public health objectives.

Competitive Landscape and Company Strategies

Competitive dynamics stem from a diverse roster of established multinational corporations and nimble regional innovators. Global leaders such as Abbott Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc. and DiaSorin S.p.A. drive innovation through integrated solutions that combine molecular platforms with digital data management. Specialized assay developers including Certest Biotec, Biopanda Reagents Ltd. and Getein Biotech focus on rapid immunoassays and lateral flow technologies. Emerging players like Abnova Corporation and Reliable Pro-detect Biomedicals Pvt. Ltd. exploit niche platforms and proprietary antibodies, while integrated service providers such as Quest Diagnostics and InBios International, Inc. offer bundled testing and analytics. Firms such as Intec Products, NovaTec Immundiagnostica GmbH and Lexicare Pharma invest heavily in point-of-care technologies and wearable biosensor research. Regional champions including Biolab Diagnostics (I) Pvt. Ltd., Saheb Pharmaceuticals LLP and Sri Pharmacare expand their footprint by tailoring kits to local epidemiology and forging distribution partnerships. This fragmentation underscores the need for collaboration, M&A, and co-development agreements to harness complementary strengths.

Actionable Recommendations for Industry Stakeholders

Industry leaders should prioritize a set of actionable initiatives to capitalize on emerging opportunities and mitigate structural challenges. First, forging strategic manufacturing alliances, including co-located reagent production near key markets, will enhance supply chain agility and reduce tariff exposure. Second, accelerating integration of real-time data analytics and cloud-based software into diagnostic platforms will differentiate offerings and meet growing demand for epidemiological intelligence. Third, investing in modular point-of-care devices that support both qualitative and quantitative assays will broaden addressable markets, from primary care to mass screening. Fourth, establishing collaborative frameworks with public health agencies and NGOs can facilitate pilot programs for wearable biosensors and mobile testing units in remote areas. Fifth, pursuing targeted licensing partnerships with assay developers can expand portfolio breadth without incurring full R&D expenditures. Lastly, aligning reimbursement strategies with payers through health economics studies that quantify early detection’s impact on hospitalization costs will bolster adoption and reimbursement coverage.

Conclusion: Navigating Opportunities and Challenges

In summary, the dengue testing ecosystem is evolving rapidly under the combined influence of cutting-edge molecular technologies, expanded point-of-care capabilities, and shifting policy landscapes. While U.S. tariffs have introduced cost pressures, they have also accelerated supply chain diversification and reshaped manufacturing footprints toward resilience. Segmentation analysis highlights varied end-user requirements, detection time sensitivities, and technology preferences, reinforcing the imperative for tailored solutions. Regional insights further underscore the importance of aligning product portfolios and go-to-market strategies with local regulatory, reimbursement, and epidemiological contexts. Against this backdrop, competitive differentiation will hinge on collaborative innovation, integrated digital offer­­ings, and strategic partnerships. By embracing these imperatives, industry participants can not only navigate current headwinds but also drive the next wave of diagnostic excellence, ultimately delivering faster, more accurate dengue testing to those who need it most.

Market Segmentation & Coverage

This research report categorizes the Dengue Testing Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Molecular Tests
    • Nucleic Acid Amplification Tests (NAATs)
    • Reverse Transcription Polymerase Chain Reaction (RT-PCR)
  • Rapid Diagnostic Tests
    • Immunochromatographic Card Test
    • Lateral Flow Tests
  • Serological Tests
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Mac-ELISA
  • Instruments
    • Analyzers
    • Detection Systems
  • Reagents And Kits
    • Antibodies
    • Antigens
  • Software And Services
    • Data Management Systems
    • Diagnostic Software Services
  • Academic Research Institutes
  • Blood Banks
  • Diagnostic Centers
    • Clinician-Operated Labs
    • Independent Diagnostic Labs
  • Hospitals And Clinics
    • Private Clinics
    • Public Hospitals
  • Early Detection
    • 1-3 Days Post Exposure
    • 4-6 Days Post Exposure
  • Late Detection
    • 7+ Days Post Exposure
  • Immunochemistry
    • Fluorescent Immunoassay
    • Radioimmunoassay
  • Molecular Diagnostics
    • Genomic Sequencing
    • Microarray Technologies
  • Point-Of-Care Technology
    • Biosensors
    • Wearable Devices
  • Qualitative Tests
  • Quantitative Tests
  • Adult Patients
  • Elderly Patients
  • Pediatric Patients
    • Adolescents
    • Neonates

This research report categorizes the Dengue Testing Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Dengue Testing Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • Abnova Corporation
  • Biogenix Inc. Pvt. Ltd.
  • Biolab Diagnostics {I}Pvt. Ltd.
  • Biopanda Reagents Ltd.
  • Certest Biotec, S.L.
  • DiaSorin S.p.A.
  • EUROIMMUN Medizinische Labordiagnostika AG
  • F. Hoffmann-La Roche Ltd.
  • Getein Biotech, Inc.
  • InBios International, Inc.
  • Intec Products, Inc.
  • Lexicare Pharma Pvt. Ltd.
  • NovaTec Immundiagnostica GmbH
  • OriGene Technologies, Inc.
  • Quest Diagnostics
  • Reckon Diagnostics Pvt. Ltd.
  • Reliable Pro-detect Biomedicals Pvt. Ltd.
  • Saheb Pharmaceuticals LLP
  • Sri Pharmacare
  • Thermo Fisher Scientific Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Dengue Testing Market, by Test Type
8.1. Introduction
8.2. Molecular Tests
8.2.1. Nucleic Acid Amplification Tests (NAATs)
8.2.2. Reverse Transcription Polymerase Chain Reaction (RT-PCR)
8.3. Rapid Diagnostic Tests
8.3.1. Immunochromatographic Card Test
8.3.2. Lateral Flow Tests
8.4. Serological Tests
8.4.1. Enzyme-Linked Immunosorbent Assay (ELISA)
8.4.2. Mac-ELISA
9. Dengue Testing Market, by Product Type
9.1. Introduction
9.2. Instruments
9.2.1. Analyzers
9.2.2. Detection Systems
9.3. Reagents And Kits
9.3.1. Antibodies
9.3.2. Antigens
9.4. Software And Services
9.4.1. Data Management Systems
9.4.2. Diagnostic Software Services
10. Dengue Testing Market, by End User
10.1. Introduction
10.2. Academic Research Institutes
10.3. Blood Banks
10.4. Diagnostic Centers
10.4.1. Clinician-Operated Labs
10.4.2. Independent Diagnostic Labs
10.5. Hospitals And Clinics
10.5.1. Private Clinics
10.5.2. Public Hospitals
11. Dengue Testing Market, by Detection Time
11.1. Introduction
11.2. Early Detection
11.2.1. 1-3 Days Post Exposure
11.2.2. 4-6 Days Post Exposure
11.3. Late Detection
11.3.1. 7+ Days Post Exposure
12. Dengue Testing Market, by Technology
12.1. Introduction
12.2. Immunochemistry
12.2.1. Fluorescent Immunoassay
12.2.2. Radioimmunoassay
12.3. Molecular Diagnostics
12.3.1. Genomic Sequencing
12.3.2. Microarray Technologies
12.4. Point-Of-Care Technology
12.4.1. Biosensors
12.4.2. Wearable Devices
13. Dengue Testing Market, by Test Nature
13.1. Introduction
13.2. Qualitative Tests
13.3. Quantitative Tests
14. Dengue Testing Market, by Patient Group
14.1. Introduction
14.2. Adult Patients
14.3. Elderly Patients
14.4. Pediatric Patients
14.4.1. Adolescents
14.4.2. Neonates
15. Americas Dengue Testing Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Dengue Testing Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Dengue Testing Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Abbott Laboratories
18.3.2. Abnova Corporation
18.3.3. Biogenix Inc. Pvt. Ltd.
18.3.4. Biolab Diagnostics {I}Pvt. Ltd.
18.3.5. Biopanda Reagents Ltd.
18.3.6. Certest Biotec, S.L.
18.3.7. DiaSorin S.p.A.
18.3.8. EUROIMMUN Medizinische Labordiagnostika AG
18.3.9. F. Hoffmann-La Roche Ltd.
18.3.10. Getein Biotech, Inc.
18.3.11. InBios International, Inc.
18.3.12. Intec Products, Inc.
18.3.13. Lexicare Pharma Pvt. Ltd.
18.3.14. NovaTec Immundiagnostica GmbH
18.3.15. OriGene Technologies, Inc.
18.3.16. Quest Diagnostics
18.3.17. Reckon Diagnostics Pvt. Ltd.
18.3.18. Reliable Pro-detect Biomedicals Pvt. Ltd.
18.3.19. Saheb Pharmaceuticals LLP
18.3.20. Sri Pharmacare
18.3.21. Thermo Fisher Scientific Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. DENGUE TESTING MARKET MULTI-CURRENCY
FIGURE 2. DENGUE TESTING MARKET MULTI-LANGUAGE
FIGURE 3. DENGUE TESTING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DENGUE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DENGUE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DENGUE TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DENGUE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DENGUE TESTING MARKET SIZE, BY DETECTION TIME, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DENGUE TESTING MARKET SIZE, BY DETECTION TIME, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST NATURE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST NATURE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DENGUE TESTING MARKET SIZE, BY PATIENT GROUP, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DENGUE TESTING MARKET SIZE, BY PATIENT GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES DENGUE TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES DENGUE TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. DENGUE TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. DENGUE TESTING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DENGUE TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DENGUE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DENGUE TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DENGUE TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DENGUE TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RT-PCR), BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DENGUE TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DENGUE TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC CARD TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DENGUE TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DENGUE TESTING MARKET SIZE, BY SEROLOGICAL TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DENGUE TESTING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DENGUE TESTING MARKET SIZE, BY MAC-ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DENGUE TESTING MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DENGUE TESTING MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DENGUE TESTING MARKET SIZE, BY DETECTION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DENGUE TESTING MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DENGUE TESTING MARKET SIZE, BY REAGENTS AND KITS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DENGUE TESTING MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC SOFTWARE SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DENGUE TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DENGUE TESTING MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DENGUE TESTING MARKET SIZE, BY CLINICIAN-OPERATED LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DENGUE TESTING MARKET SIZE, BY INDEPENDENT DIAGNOSTIC LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DENGUE TESTING MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DENGUE TESTING MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DENGUE TESTING MARKET SIZE, BY DETECTION TIME, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DENGUE TESTING MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DENGUE TESTING MARKET SIZE, BY 1-3 DAYS POST EXPOSURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DENGUE TESTING MARKET SIZE, BY 4-6 DAYS POST EXPOSURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DENGUE TESTING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DENGUE TESTING MARKET SIZE, BY LATE DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DENGUE TESTING MARKET SIZE, BY 7+ DAYS POST EXPOSURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DENGUE TESTING MARKET SIZE, BY LATE DETECTION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DENGUE TESTING MARKET SIZE, BY IMMUNOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DENGUE TESTING MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DENGUE TESTING MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DENGUE TESTING MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DENGUE TESTING MARKET SIZE, BY GENOMIC SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DENGUE TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT-OF-CARE TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL DENGUE TESTING MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL DENGUE TESTING MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT-OF-CARE TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST NATURE, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL DENGUE TESTING MARKET SIZE, BY QUALITATIVE TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL DENGUE TESTING MARKET SIZE, BY QUANTITATIVE TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL DENGUE TESTING MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL DENGUE TESTING MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL DENGUE TESTING MARKET SIZE, BY ELDERLY PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL DENGUE TESTING MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL DENGUE TESTING MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL DENGUE TESTING MARKET SIZE, BY NEONATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL DENGUE TESTING MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS DENGUE TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS DENGUE TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS DENGUE TESTING MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS DENGUE TESTING MARKET SIZE, BY REAGENTS AND KITS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS DENGUE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS DENGUE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS DENGUE TESTING MARKET SIZE, BY DETECTION TIME, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS DENGUE TESTING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS DENGUE TESTING MARKET SIZE, BY LATE DETECTION, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS DENGUE TESTING MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS DENGUE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS DENGUE TESTING MARKET SIZE, BY POINT-OF-CARE TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS DENGUE TESTING MARKET SIZE, BY TEST NATURE, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS DENGUE TESTING MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS DENGUE TESTING MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA DENGUE TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA DENGUE TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA DENGUE TESTING MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA DENGUE TESTING MARKET SIZE, BY REAGENTS AND KITS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA DENGUE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA DENGUE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA DENGUE TESTING MARKET SIZE, BY DETECTION TIME, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA DENGUE TESTING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA DENGUE TESTING MARKET SIZE, BY LATE DETECTION, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA DENGUE TESTING MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA DENGUE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA DENGUE TESTING MARKET SIZE, BY POINT-OF-CARE TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA DENGUE TESTING MARKET SIZE, BY TEST NATURE, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA DENGUE TESTING MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA DENGUE TESTING MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL DENGUE TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL DENGUE TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL DENGUE TESTING MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL DENGUE TESTING MARKET SIZE, BY REAGENTS AND KITS, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL DENGUE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL DENGUE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL DENGUE TESTING MARKET SIZE, BY DETECTION TIME, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL DENGUE TESTING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL DENGUE TESTING MARKET SIZE, BY LATE DETECTION, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL DENGUE TESTING MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL DENGUE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL DENGUE TESTING MARKET SIZE, BY POINT-OF-CARE TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL DENGUE TESTING MARKET SIZE, BY TEST NATURE, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL DENGUE TESTING MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL DENGUE TESTING MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 138. CANADA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 139. CANADA DENGUE TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 140. CANADA DENGUE TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 141. CANADA DENGUE TESTING MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 142. CANADA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 143. CANADA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 144. CANADA DENGUE TESTING MARKET SIZE, BY REAGENTS AND KITS, 2018-2030 (USD MILLION)
TABLE 145. CANADA DENGUE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 146. CANADA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. CANADA DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 148. CANADA DENGUE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 149. CANADA DENGUE TESTING MARKET SIZE, BY DETECTION TIME, 2018-2030 (USD MILLION)
TABLE 150. CANADA DENGUE TESTING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 151. CANADA DENGUE TESTING MARKET SIZE, BY LATE DETECTION, 2018-2030 (USD MILLION)
TABLE 152. CANADA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 153. CANADA DENGUE TESTING MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 154. CANADA DENGUE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 155. CANADA DENGUE TESTING MARKET SIZE, BY POINT-OF-CARE TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 156. CANADA DENGUE TESTING MARKET SIZE, BY TEST NATURE, 2018-2030 (USD MILLION)
TABLE 157. CANADA DENGUE TESTING MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 158. CANADA DENGUE TESTING MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 159. MEXICO DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 160. MEXICO DENGUE TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 161. MEXICO DENGUE TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 162. MEXICO DENGUE TESTING MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 163. MEXICO DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 164. MEXICO DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 165. MEXICO DENGUE TESTING MARKET SIZE, BY REAGENTS AND KITS, 2018-2030 (USD MILLION)
TABLE 166. MEXICO DENGUE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 167. MEXICO DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. MEXICO DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 169. MEXICO DENGUE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 170. MEXICO DENGUE TESTING MARKET SIZE, BY DETECTION TIME, 2018-2030 (USD MILLION)
TABLE 171. MEXICO DENGUE TESTING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 172. MEXICO DENGUE TESTING MARKET SIZE, BY LATE DETECTION, 2018-2030 (USD MILLION)
TABLE 173. MEXICO DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 174. MEXICO DENGUE TESTING MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 175. MEXICO DENGUE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 176. MEXICO DENGUE TESTING MARKET SIZE, BY POINT-OF-CARE TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 177. MEXICO DENGUE TESTING MARKET SIZE, BY TEST NATURE, 2018-2030 (USD MILLION)
TABLE 178. MEXICO DENGUE TESTING MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 179. MEXICO DENGUE TESTING MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES DENGUE TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES DENGUE TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 183. UNITED STATES DENGUE TESTING MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 184. UNITED STATES DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 185. UNITED STATES DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 186. UNITED STATES DENGUE TESTING MARKET SIZE, BY REAGENTS AND KITS, 2018-2030 (USD MILLION)
TABLE 187. UNITED STATES DENGUE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 188. UNITED STATES DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. UNITED STATES DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 190. UNITED STATES DENGUE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 191. UNITED STATES DENGUE TESTING MARKET SIZE, BY DETECTION TIME, 2018-2030 (USD MILLION)
TABLE 192. UNITED STATES DENGUE TESTING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 193. UNITED STATES DENGUE TESTING MARKET SIZE, BY LATE DETECTION, 2018-2030 (USD MILLION)
TABLE 194. UNITED STATES DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 195. UNITED STATES DENGUE TESTING MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 196. UNITED STATES DENGUE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 197. UNITED STATES DENGUE TESTING MARKET SIZE, BY POINT-OF-CARE TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 198. UNITED STATES DENGUE TESTING MARKET SIZE, BY TEST NATURE, 2018-2030 (USD MILLION)
TABLE 199. UNITED STATES DENGUE TESTING MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 200. UNITED STATES DENGUE TESTING MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 201. UNITED STATES DENGUE TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY REAGENTS AND KITS, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 212. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 213. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY DETECTION TIME, 2018-2030 (USD MILLION)
TABLE 214. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 215. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY LATE DETECTION, 2018-2030 (USD MILLION)
TABLE 216. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 218. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 219. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY POINT-OF-CARE TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 220. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY TEST NATURE, 2018-2030 (USD MILLION)
TABLE 221. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 222. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 223. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 224. AUSTRALIA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 225. AUSTRALIA DENGUE TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 226. AUSTRALIA DENGUE TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 227. AUSTRALIA DENGUE TESTING MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 228. AUSTRALIA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 230. AUSTRALIA DENGUE TESTING MARKET SIZE, BY REAGENTS AND KITS, 2018-2030 (USD MILLION)
TABLE 231. AUSTRALIA DENGUE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 232. AUSTRALIA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. AUSTRALIA DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 234. AUSTRALIA DENGUE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 235. AUSTRALIA DENGUE TESTING MARKET SIZE, BY DETECTION TIME, 2018-2030 (USD MILLION)
TABLE 236. AUSTRALIA DENGUE TESTING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 237. AUSTRALIA DENGUE TESTING MARKET SIZE, BY LATE DETECTION, 2018-2030 (USD MILLION)
TABLE 238. AUSTRALIA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 239. AUSTRALIA DENGUE TESTING MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 240. AUSTRALIA DENGUE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 241. AUSTRALIA DENGUE TESTING MARKET SIZE, BY POINT-OF-CARE TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 242. AUSTRALIA DENGUE TESTING MARKET SIZE, BY TEST NATURE, 2018-2030 (USD MILLION)
TABLE 243. AUSTRALIA DENGUE TESTING MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 244. AUSTRALIA DENGUE TESTING MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 245. CHINA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 246. CHINA DENGUE TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 247. CHINA DENGUE TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 248. CHINA DENGUE TESTING MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 249. CHINA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 250. CHINA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 251. CHINA DENGUE TESTING MARKET SIZE, BY REAGENTS AND KITS, 2018-2030 (USD MILLION)
TABLE 252. CHINA DENGUE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 253. CHINA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. CHINA DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 255. CHINA DENGUE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 256. CHINA DENGUE TESTING MARKET SIZE, BY DETECTION TIME, 2018-2030 (USD MILLION)
TABLE 257. CHINA DENGUE TESTING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 258. CHINA DENGUE TESTING MARKET SIZE, BY LATE DETECTION, 2018-2030 (USD MILLION)
TABLE 259. CHINA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 260. CHINA DENGUE TESTING MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 261. CHINA DENGUE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 262. CHINA DENGUE TESTING MARKET SIZE, BY POINT-OF-CARE TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 263. CHINA DENGUE TESTING MARKET SIZE, BY TEST NATURE, 2018-2030 (USD MILLION)
TABLE 264. CHINA DENGUE TESTING MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 265. CHINA DENGUE TESTING MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 266. INDIA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 267. INDIA DENGUE TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 268. INDIA DENGUE TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 269. INDIA DENGUE TESTING MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 270. INDIA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 271. INDIA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 272. INDIA DENGUE TESTING MARKET SIZE, BY REAGENTS AND KITS, 2018-2030 (USD MILLION)
TABLE 273. INDIA DENGUE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 274. INDIA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. INDIA DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 276. INDIA DENGUE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 277. INDIA DENGUE TESTING MARKET SIZE, BY DETECTION TIME, 2018-2030 (USD MILLION)
TABLE 278. INDIA DENGUE TESTING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 279. INDIA DENGUE TESTING MARKET SIZE, BY LATE DETECTION, 2018-2030 (USD MILLION)
TABLE 280. INDIA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 281. INDIA DENGUE TESTING MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 282. INDIA DENGUE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 283. INDIA DENGUE TESTING MARKET SIZE, BY POINT-OF-CARE TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 284. INDIA DENGUE TESTING MARKET SIZE, BY TEST NATURE, 2018-2030 (USD MILLION)
TABLE 285. INDIA DENGUE TESTING MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 286. INDIA DENGUE TESTING MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 287. INDONESIA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 288. INDONESIA DENGUE TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 289. INDONESIA DENGUE TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 290. INDONESIA DENGUE TESTING MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 291. INDONESIA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 292. INDONESIA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 293. INDONESIA DENGUE TESTING MARKET SIZE, BY REAGENTS AND KITS, 2018-2030 (USD MILLION)
TABLE 294. INDONESIA DENGUE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 295. INDONESIA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 296. INDONESIA DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 297. INDONESIA DENGUE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 298. INDONESIA DENGUE TESTING MARKET SIZE, BY DETECTION TIME, 2018-2030 (USD MILLION)
TABLE 299. INDONESIA DENGUE TESTING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 300. INDONESIA DENGUE TESTING MARKET SIZE, BY LATE DETECTION, 2018-2030 (USD MILLION)
TABLE 301. INDONESIA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 302. INDONESIA DENGUE TESTING MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 303. INDONESIA DENGUE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 304. INDONESIA DENGUE TESTING MARKET SIZE, BY POINT-OF-CARE TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 305. INDONESIA DENGUE TESTING MARKET SIZE, BY TEST NATURE, 2018-2030 (USD MILLION)
TABLE 306. INDONESIA DENGUE TESTING MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 307. INDONESIA DENGUE TESTING MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 308. JAPAN DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 309. JAPAN DENGUE TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 310. JAPAN DENGUE TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 311. JAPAN DENGUE TESTING MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 312. JAPAN DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 313. JAPAN DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 314. JAPAN DENGUE TESTING MARKET SIZE, BY REAGENTS AND KITS, 2018-2030 (USD MILLION)
TABLE 315. JAPAN DENGUE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 316. JAPAN DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 317. JAPAN DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 318. JAPAN DENGUE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 319. JAPAN DENGUE TESTING MARKET SIZE, BY DETECTION TIME, 2018-2030 (USD MILLION)
TABLE 320. JAPAN DENGUE TESTING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 321. JAPAN DENGUE TESTING MARKET SIZE, BY LATE DETECTION, 2018-2030 (USD MILLION)
TABLE 322. JAPAN DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 323. JAPAN DENGUE TESTING MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 324. JAPAN DENGUE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 325. JAPAN DENGUE TESTING MARKET SIZE, BY POINT-OF-CARE TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 326. JAPAN DENGUE TESTING MARKET SIZE, BY TEST NATURE, 2018-2030 (USD MILLION)
TABLE 327. JAPAN DENGUE TESTING MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 328. JAPAN DENGUE TESTING MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 329. MALAYSIA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 330. MALAYSIA DENGUE TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 331. MALAYSIA DENGUE TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 332. MALAYSIA DENGUE TESTING MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 333. MALAYSIA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 334. MALAYSIA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 335. MALAYSIA DENGUE TESTING MARKET SIZE, BY REAGENTS AND KITS, 2018-2030 (USD MILLION)
TABLE 336. MALAYSIA DENGUE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 337. MALAYSIA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 338. MALAYSIA DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 339. MALAYSIA DENGUE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 340. MALAYSIA DENGUE TESTING MARKET SIZE, BY DETECTION TIME, 2018-2030 (USD MILLION)
TABLE 341. MALAYSIA DENGUE TESTING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 342. MALAYSIA DENGUE TESTING MARKET SIZE, BY LATE DETECTION, 2018-2030 (USD MILLION)
TABLE 343. MALAYSIA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 344. MALAYSIA DENGUE TESTING MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 345. MALAYSIA DENGUE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 346. MALAYSIA DENGUE TESTING MARKET SIZE, BY POINT-OF-CARE TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 347. MALAYSIA DENGUE TESTING MARKET SIZE, BY TEST NATURE, 2018-2030 (USD MILLION)
TABLE 348. MALAYSIA DENGUE TESTING MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 349. MALAYSIA DENGUE TESTING MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 350. PHILIPPINES DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 351. PHILIPPINES DENGUE TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 352. PHILIPPINES DENGUE

Companies Mentioned

  • Abbott Laboratories
  • Abnova Corporation
  • Biogenix Inc. Pvt. Ltd.
  • Biolab Diagnostics {I}Pvt. Ltd.
  • Biopanda Reagents Ltd.
  • Certest Biotec, S.L.
  • DiaSorin S.p.A.
  • EUROIMMUN Medizinische Labordiagnostika AG
  • F. Hoffmann-La Roche Ltd.
  • Getein Biotech, Inc.
  • InBios International, Inc.
  • Intec Products, Inc.
  • Lexicare Pharma Pvt. Ltd.
  • NovaTec Immundiagnostica GmbH
  • OriGene Technologies, Inc.
  • Quest Diagnostics
  • Reckon Diagnostics Pvt. Ltd.
  • Reliable Pro-detect Biomedicals Pvt. Ltd.
  • Saheb Pharmaceuticals LLP
  • Sri Pharmacare
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Dengue Testing - Global Strategic Business Report - Product Image

Dengue Testing - Global Strategic Business Report

  • Report
  • 158 Pages
  • Global
From
Dengue Testing Market Report by Test Type, End User, and Region 2025-2033 - Product Image

Dengue Testing Market Report by Test Type, End User, and Region 2025-2033

  • Report
  • 144 Pages
  • Global
From
Dengue Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Dengue Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 240 Pages
  • Global
From
Arbovirus Testing Market by Type, Component, Indication, End-User - Global Forecast 2025-2030 - Product Image

Arbovirus Testing Market by Type, Component, Indication, End-User - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From

About the Dengue Test Market

The Dengue Test market is a subset of the Diagnostics industry, which focuses on the detection and diagnosis of diseases. Dengue is a mosquito-borne viral infection that is endemic in tropical and subtropical regions. Diagnostic tests for dengue are used to detect the presence of the virus in a patient's blood sample. These tests are used to diagnose dengue fever, as well as to differentiate between the four serotypes of the virus. The Dengue Test market is driven by the increasing prevalence of dengue fever, as well as the growing demand for rapid and accurate diagnostic tests. The market is also driven by the increasing availability of diagnostic kits and the development of new technologies for the detection of dengue. Some of the major players in the Dengue Test market include Abbott Laboratories, Bio-Rad Laboratories, DiaSorin, F. Hoffmann-La Roche, and Siemens Healthineers. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.